Kornimate/medical-research-clean huggingface dataset:
nasal intubation：a comparison of different endotracheal tubes

Conditions: Intubation Complication

Summary: either uses two different endotracheal tubes to pass the nasal cavity and to compare the effects on the secretion and bleeding volume of patients during intubation to facilitate nasotracheal tube advancement.

1. assess the patient's airway before intubation. ekg, blood pressure and spo2 are monitored during the process. 2. randomly divided into two groups：henan tuoren endotracheal tube and smiths portex tracheal tubes. 3. sedation process：give fentanyl 1 ug/kg according to the patient's weight via iv. 4. give 1.5ml of lidocaine without epinephrine and 0.5ml of lidocaine with epinephrine to reduce intranasal bleeding. 5. sedative injection：give fentanyl 1ug/kg + thiamylal 5mg/kg + rocuronium 1mg/kg 6. anesthesia intubation inducer：propofol 1mg/kg 7. intubation 8. record the bleeding of the oropharyngeal and nasal mucosa、intubation time、intubation difficult scale (ids score) and number of intubations during intubation. 9. record oropharynx、nostril and oropharynx bleeding in 3 minutes after completion of intubation. 10. evaluate the patient's sore throat, hoarse voice, dysphagia, nasal congestion, nose bleeding, and nasal pain every other day.

Eligibility criteria:
inclusion criteria: * age:20-65 years * undergoing oro-maxillofacial surgery * opening mouth \> 3 cm * denied any systemic disease. * american society of anesthesiologists (asa) class:i-iii exclusion criteria: * difficult airway assessed (limited mouth opening, limited neck motion, and thyromental distance \< 6cm) * previous head and neck surgery history * upper abnormal airway diagnosed * easily epistaxis * both sides nasal cavities obstruction

Keywords: endotracheal tube intubation general anesthesia (etga) nasotracheal tube
the periodontal status and failure rates with different retainer bonding techniques using one-step adhesive

Conditions: Periodontal Inflammation

Summary: the aim of this study was to evaluate fixed retainers, bonded with either direct or indirect techniques using one- or two-step adhesives, in terms of periodontal status and failure rates.


Eligibility criteria:
inclusion criteria: * good treatment outcomes * good oral hygiene * no systemic or periodontal problems * no extraction or missing anterior teeth and restorations exclusion criteria: - patients unwilling to wear a fixed retainer

Keywords: failure rate periodontal status retainer
identification of human biomarkers predictive of diabetes remission in type 2 diabetes patient (bariakines)

Conditions: Type 2 Diabetes

Summary: this study focuses on identifying potentially predictive human circulating adipocyte and muscle biomarkers of diabetes remission after bariatric surgery in obese type 2 diabetic (t2d) subjects.

the study team at the institute of metabolic and cardiovascular diseases has recently identified several potential biomarkers (secreted by skeletal muscle and adipose tissue) of glucose homeostasis control using secretomic and metabolomic analyses. the goal of this study is to assess whether the addition of 9 adipocytes and myocytes plasma level could be associated with type 2 diabetes remission one year after bariatric surgery and would improve established clinical models of prediction of diabetes remission. thus, obese type 2 diabetes patients undergoing bariatric surgery will have 2 blood samples, a muscle sample and one adipose tissue sample withdrawn during the study. from those samples, concentrations of 9 candidate proteins is measured : gdf6, inhbb, il17b, tgfb2, timp1, vtn, mdk, gdf15, and apom

Eligibility criteria:
inclusion criteria: * obese patients of at least grade 2 (body mass index ≥ 35 kg/m²) * type 2 diabetics * about to undergo bariatric surgery at the toulouse university hospital * affiliated or beneficiaries of a social security plan. * having provided a free, informed and written consent, signed exclusion criteria: * type 1 diabetic subjects or maturity-onset diabetes of the youth. * pregnant and breastfeeding women. * vulnerable persons as defined in the public health code: protected adults (guardianship, curators), unable to express their consent.

Keywords: obesity bariatric surgery candidate proteins biomarkers
immunogenicity of 9-valent hpv vaccine

Conditions: Human Papilloma Virus Infection

Summary: human papillomavirus (hpv) causes the most prevalent sexually transmitted infections in the world. the nonavalent hpv vaccine (9vhpv) provides protection against 9 high-risk hpv serotypes, responsible for causing approximately 90% of cervical and other hpv-related anogenital cancers, as well as 90% of genital warts. the risk of cancer is substantially increased among immunocompromised patients. although studies have demonstrated seroprotection among children and adolescents, boys and girls, with the 9vhpv vaccine, the immunogenicity of this vaccine has been poorly explored in immunocompromised children and adolescents (including transplant patients, and those infected with human immunodeficiency virus (hiv)). several factors, including the immunological consequences of vertically acquired infection, immunosuppressive therapies and age, could lead to an increased risk of infection in children and adolescents who are immunocompromised. lower immunogenicity in these populations. these children may have a poor response to vaccines and therefore require additional doses. markers such as cd4/cd8 or torque teno virus (ttv) replication could be linked to immunogenicity and thus serve as predictors of efficacy for routine clinical practice.


Eligibility criteria:
inclusion criteria: * children or adolescents 9 to \<18 years of age * willing to sign consent/assent form * if hiv positive, under art and undetectable viral load and cd4 cell count \>200/mm3 (at least 6 months) * if the patient has received chemotherapy or is a sot/hsct recipient, referred for immunizations after adequate immune reconstitution according to routine clinical practice exclusion criteria: * previous history of warts and/or anal cancer. * previous immunization with any hpv vaccine. * age below 9. * patients who for any reason should not be included in the study according to the evaluation of the research team.
a comparative prospective study of the arthroscopic meniscus repair methods

Conditions: Meniscus Tear Caused by a Traumatic Event

Summary: performing arthroscopic meniscus repair following a traumatic meniscus tear as an alternative to a meniscectomy is now an acceptable choice. preserving meniscus tissues is crucial due to the significant role they play as an essential part of the knee joint. it is essential to comprehend the additional tools that can impact the recovery of the meniscus after suturing. patients have been randomly assigned into two groups using the computerised application "randomizer for clinical trial lite," and the treatment outcomes were compared after one year. one group of patients has received a standard meniscus suturing technique, whereas another group has experienced the meniscus suturing treatment with an additional fibrin clot approach. data pertaining to demographics, clinical characteristics, radiological findings, and survey responses have been carefully collected prospectively.


Eligibility criteria:
inclusion criteria: * individuals who provide consent to participate in the study, including patients and their care providers. the inclusion criteria for this study are as follows: being under the age of 19, having a traumatic isolated full-thickness meniscal tear longer than 1cm that has been confirmed by both preoperative mri and arthroscopy, and not having undergone any previous surgery on the affected knee. exclusion criteria: * this investigation excludes patients with developmental disabilities who are unable to read or interpret in their native language.

Keywords: meniscus tear, meniscus repair, knee, fibrin clot, arthroscopy
group education helps smoking cessation and hypertension control

Conditions: Smoking Cessation; Hypertension

Summary: smoking elderly males with stage 1 and 2 hypertension who currently smoked at least one cigarette per day and were willing to quit smoke will be invited to this cluster randomized, controlled, interventional, open clinical trial. the investigators will provide participants with group education of smoking cessation and their blood pressure measured at clinic at the sixth month is the primary endpoint. the investigators aim to explore how group education of smoking cessation effects smoking cessation, hypertension control and cardiovascular events.


Eligibility criteria:
inclusion criteria: * signed the informed consent * aged 65 to 84 * new-onset hypertension or poorly controlled hypertension (140mmhg≤systolic blood pressure\<180mmhg and (or) 90mmhg≤ diastolic blood pressure\<110mmhg) * smoked last week and smoked more than 1 cigarette per day on average * be willing to quit smoking * can communicate normally and cooperate in blood pressure measurements, finishing questionnaires * complete interventions and follow-up consistently exclusion criteria: * home systolic blood pressure\<130mmhg and (or) home diastolic blood pressure\<80 mmhg * severe communication difficulties (aphasia, hearing impairment, etc.) * suffering from mental disorders such as anxiety and depression * cancer confirmed * with previous serious cardiovascular events such as acute coronary syndrome, acute left heart failure, stroke or with specific cardiovascular therapeutic device such as pacemakers * other serious physical illness or illness identified by investigators that unable to participant in study * using specific non-permitted medication currently

Keywords: group education smoking cessation blood pressure
effect of extracorporeal co2 removal in stable hypercapnic copd patients

Conditions: Chronic Obstructive Pulmonary Disease Patients; Chronic Respiratory Failure

Summary: chronic hypercapnic respiratory failure is common in stable copd patients in a terminal phase of their disease in an attempt to correct or slow down the rate of rise of paco2, long-term noninvasive mechanical ventilation (niv) has been proposed. only very few studies demonstrated the clinical efficacy of niv. indeed this technique is not always well tolerated and therefore it may be effective only in a subset of patients the aim of this study is to assess the feasibility and safety of "one shot" extrcorporeal co2 removal device, in reducing the paco2 level

chronic hypercapnic respiratory failure is common in stable copd patients in a terminal phase of their disease in an attempt to correct or slow down the rate of rise of paco2, long-term noninvasive mechanical ventilation (niv) has been proposed. only very few studies demonstrated the clinical efficacy of niv. indeed this technique is not always well tolerated and therefore it may be effective only in a subset of patients recently extracorporeal co2 removal have been shown to avoid the need of endotracheal intubation in copd patients with an episode of acute hypercapnic respiratory failure in this pilot physiological study we want to assess the safety and efficacy of this technique in reducing the paco2 level in those copd patients with chronic hypercapnic respiratory failure non responding to chronic niv.

Eligibility criteria:
inclusion criteria: * copd ( fev1/cvf \<0.70 post bronchodilation) * stable paco2 \>55 mmhg non respondent to long-term niv (at least one week). this means a decrease in paco2 during spontaneous breathing, at least 4 hrs after the termination of niv, of\< 6% * ph \> 7.35 * clinical stability exclusion criteria: * mean arterial pressure \< 60 mmhg * contra-indication to heparin * body mass index (bmi) \> 30 kg/m2; * presence of sleep apnea or overall syndrome
documentation of patient outcomes for ssg/allopurinol combination treatment in ethiopia

Conditions: Cutaneous Leishmaniasis

Summary: outcomes of patients receiving ssg and allopurinol combination have never been documented systematically in ethiopia. therefore, it is not known how effective this combination is. this study will provide evidence to help clinicians make the best choice regarding treatment for complicated cutaneous leishmaniasis (cl) cases. due to diversity in host-pathogen interactions across the different cl forms, early immunological correlates associated with treatment responsiveness and unresponsiveness could help treatment recommendation and provide us with the basis to develop new diagnostic and treatment strategies. this study aims to document treatment outcomes of patients with clcl, mcl, and dcl receiving systemic treatment using ssg and allopurinol combination within a routine care setting located in a highly endemic area in ethiopia.

cutaneous leishmaniasis (cl) in ethiopia causes severe dermatological mutilations. forms that require systemic treatment are complicated localized cutaneous leishmaniasis (clcl), mucocutaneous leishmaniasis (mcl), and diffuse cutaneous leishmaniasis (dcl). the clinical presentation of cl depends on various factors including parasite species, infection history and differences in the immune response. national guidelines recommend equally all drugs that are also used for visceral leishmaniasis treatment. sodium stibogluconate (ssg) is one of these recommended medications. however, dermatologists in ethiopia also use a combination of ssg and allopurinol for treatment of complicated cutaneous leishmaniasis. outcomes of patients receiving ssg and allopurinol combination have never been documented systematically in ethiopia. therefore, it is not known how effective this combination is. this study will provide evidence to help clinicians make the best choice regarding treatment for complicated cl cases. due to diversity in host-pathogen interactions across the different cl forms, early immunological correlates associated with treatment responsiveness and unresponsiveness could help treatment recommendation and provide us with the basis to develop new diagnostic and treatment strategies. this study aims to document treatment outcomes of patients with clcl, mcl, and dcl receiving systemic treatment using ssg and allopurinol combination within a routine care setting located in a highly endemic area in ethiopia.

Eligibility criteria:
inclusion criteria: * clinically or microscopically confirmed diagnosis of mcl, dcl or complicated lcl * clinical routine care decision to initiate systemic cl treatment using ssg with allopurinol * willing and able to provide informed consent exclusion criteria: * medical emergencies, underlying chronic conditions or other circumstances that make participation in this study medically or otherwise inadvisable study sample collection only for age 18 and above
randomized controlled trial comparing acellular collagen biomesh (pelvisoft) to polypropylene mesh(pelvitex) for sacral colpopexy

Conditions: Uterine Prolapse

Summary: this research protocol is a randomized controlled trial. it is being done to compare and find out the relative differences between the materials, (pelivisoft) "natural organic mesh" to poly propylene mesh (pelvitex) "manmade mesh" after a surgery known as sacral colpopexy. this surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum). these materials are both fda approved and widely used. the following objectives: anatomic outcomes, graft-related complications between the two materials, changes in pelvic organ prolapse-related quality of life, subjective changes in sexual function,changes in bowel function and the prolapse related pain present after sacral colpopexy will be evaluated. the study visits are all under standard of care. study questionnaires are unique to the study and will be completed at the enrollment in hospital, 2, 6,12 weeks, 6 months and one year visits the questionnaires are related to bowel function, bladder function, prolapse and sexual activity. permission will be requested to contact the patient again 5 years after surgery. contact in the future will in no way obligate the patient to participate. there may or may not be direct medical benefits to the participant. decreased risk of erosion may be a possible benefit if placed in the organic "natural" arm of the study. the information learned from this study may benefit other patients in the future


Eligibility criteria:
inclusion criteria: * greater than 18 years of age exclusion criteria: * prior sacral colpopexy or rectopexy contraindication to surgery based on co-existent medical condition desire for expectant management or pessary use pregnancy or the desire for pregnancy within 24 months of the sacral colpopexy procedure

Keywords: compare the relative differences between the organic and sythentic materials for sacryl colpopexy.
patient outcomes reporting for timely assessments of life with depression: portal-depression

Conditions: Depression; Depressive Disorder, Major

Summary: currently, very little research exists on whether patient portals could be used to integrate patient-reported outcome (pro) measurement into the electronic health record (ehr) and clinical practice, even though 87% of ambulatory care practices have ehrs and 88% of u.s. adults have access to the internet. to date, no randomized controlled trial has examined whether patient portals can be used to collect pro measures. the goal of this study is to implement the integration of a computerized adaptive test (cat) for patient-reported outcome (pro) measurement of depression symptoms into an electronic health record (ehr) and evaluate the effectiveness of collecting cat pros via an ehr patient portal in two randomized controlled trials. this study will advance the science of implementation of patient-centered outcomes research into clinical practice, as well as the evidence for high quality, accessible care.

the overall goal of this proposal is to implement the integration of the computerized adaptive test for mental health (cat-mh) into an ehr for a healthcare system and evaluate the effectiveness of collecting cat-mh pros via an ehr-tethered patient portal (mychart) vs. usual care in two randomized controlled trials. the first aim of this study will consist of a randomized controlled trial comparing screening rates among adult primary care patients with an active patient portal account (mychart) and due for depression screening who receive usual care (cat-mh screenings during routine clinic visits) vs. mychart population-based cat-mh screenings. the second aim of this study involves a randomized controlled trial comparing depression remission rates among patients with active moderate-to-severe mdd who receive usual care vs. mychart cat-mh measurement-based care. in addition, we will examine the resources needed to integrate the cat-mh into the ehr and design the health it strategy for collecting pros via the patient portal.

Eligibility criteria:
inclusion criteria: * 18 years or older * considered an active clinic patient at the start date of the intervention * have an active mychart account that is not managed by a proxy * receive care from a participating pcp * due for depression screening (screening arms) or active depression (monitoring arms) exclusion criteria: * under 18 years of age * bipolar disorder
evaluation of mechanical characteristics of tendons of athletes using sonography

Conditions: Overuse Injury; Rotator Cuff Injuries

Summary: the investigators analyzed the strain of the rotator cuff tendon of baseball pitchers obtained using ultrasonography and compared the change in peak tendon strain before and after the regular season.


Eligibility criteria:
inclusion criteria: * baseball pitchers in city baseball team exclusion criteria: * history of shoulder disorder or surgery
lupus nephritis biomarker study: baseline characteristics of patients

Conditions: Lupus Nephritis

Summary: this is an exploratory study. no formal hypothesis will be tested. the objectives of this study are to follow lupus nephritis patients over a period of 12 months to: * establish the baseline biomarker characteristics of patients * determine the variability of biomarker measures over time * correlate biomarkers with disease phenotype


Eligibility criteria:
inclusion criteria: * adults between 18 and 80 years of age, inclusive * diagnosis of sle by acr criteria and biopsy-proven isn/rps class iii or iv lupus glomerulonephritis within 2 years * persistently active nephritis defined as proteinuria greater than or equal to 1.0 g/day for 3 months or more, and at least 1 of the following: * hematuria (greater than or equal to 5 rbc/hpf) on 2 or more urinalyses done greater than or equal to 2 weeks apart * anti-dsdna positive or anti-smith positive, or * low c3 or c4 complement level. (d) stable immunosuppression consisting of mycophenolate mofetil (mmf) 13 g/day with/without corticosteroids up to prednisone equivalent of 15 mg/day, or azathioprine 13 mg/kg/day with/without corticosteroids up to prednisone equivalent of 20 mg/day. * stable dose of ace inhibitor/arb for 4 weeks prior to study enrollment, unless previously intolerant to or having a contraindication to ace inhibitors and arbs * if using oral corticosteroids, must be on a stable dose equivalent to less than or equal to 15 mg/day of prednisone for at least 4 weeks prior to study enrollment. if currently not using corticosteroids, the subject must not have received oral corticosteroids for at least 4 weeks prior study enrollment. * clarification of inclusion criteria for controls: any patient with an idiopathic glomerular disease who does not have lupus nephritis. this includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and iga nephropathy. exclusion criteria: * b-cell depletion therapy in past 1 yr, or evidence of persistent b cell depletion at the time of screening. * received an investigational drug (including vaccines) or used an investigational medical device within 3 months of study enrollment or within 5 half-lives of agent, whichever is longer.

Keywords: lupus nephritis
measurement of cerebral rso2 levels during sleep in children with suspected obstructive sleep apnea

Conditions: Obstructive Sleep Apnea; Pediatric Sleep Apnea

Summary: the gold standard of obstructive sleep apnea (osa) is (psg)polysomnography. during the examination, the patient is monitored by saturation, eeg and other measurements. near infrared spectroscopy is an uprising technology allowing non invasive measurement of the frontal lobe oxygenation. it is painless and does not have side effects. we believe that brain saturation will be more accurate then peripheral pulse oximeter and will be better correlated with the clinical presentation of osa.

a prospective cohort study study group - pediatric population referred to psg in dana duek hospital. after informed consent received from the parents, the parents will fulfill "connors" (age 6 +) \& "brief" (age 4-6) questionnaires. during the psg, the brain saturation will be monitored by invos(tm) medtronic device. they will be monitored \& synchronized with the peripheral saturation documented performed as part of the psg examination. the brain saturation \& peripheral saturation levels will be compared and both will be correlated to the questionnaires \& ahi.

Eligibility criteria:
inclusion criteria: * 4-16 y/o pediatric population referred for psg in dana hospital exclusion criteria: * down synd. * craniofacial malformation * ppd